publication venue for
- BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. 3:iii5-iii5. 2021
- BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis. 3:iii5-iii5. 2021
- NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. 3:ii5-ii5. 2021
- 25. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF NCCTG N107C/CEC.3 AND N0574 (ALLIANCE) RANDOMIZED CLINICAL TRIALS. 2:ii4-ii4. 2020
- 37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. 2:ii6-ii7. 2020
- 39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS. 2:ii7-ii7. 2020
- 47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES. 2:ii9-ii9. 2020
- BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES. 1:i5-i5. 2019
- RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933. 1:i22-i22. 2019